早期的辅助治疗,尤其是辅助化疗研究,几乎全在组织学有腋下淋巴结受累病人中进行。因为辅助治疗毒性太大,除非完全证实其对,人有益,否则不适用于预后很好的病人。所以病这种疗法只限于淋巴结阳性病人。但是,在确认辅助治疗能明显延长几乎所有淋巴结阳性病人的无复发生存和一些亚群病人的总生存以 Early adjuvant therapy, especially adjuvant chemotherapy, was performed almost exclusively in patients with axillary lymph node involvement in histology. Because the adjuvant treatment is too toxic, it does not apply to patients with good prognosis unless it is fully proven to be beneficial. Therefore, this therapy is limited to lymph node positive patients. However, confirming that adjuvant therapy can significantly prolong the recurrence-free survival of almost all lymph node-positive patients and the overall survival of some subsets of patients.